Dr. Jean-Pierre Pouget
Dr Jean-Pierre Pouget obtained his PhD thesis in Radiobiology in 2000 from the Curie Institute in Paris and carried-out a post-doctoral fellowship in the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry. He then moved to Paris to the French Radiation Protection and Nuclear Safety Agency (IRSN) for 4 years where he worked on radiation casualties.
After moving to Montpellier, he joined the French National Institute for Health and Medical research (INSERM) where he is now leader of the “Radiobiology and Targeted Radiotherapy” team at the Cancer Research Institute of Montpellier (INSERM, France).
He develops new radiopharmaceuticals for cancer imaging and therapy with a special focus on radiobiology. More specifically, his team has developed murine and humanized monoclonal antibodies (mAbs) directed against the anti-Müllerian hormone receptor (MISRII) overexpressed in ovarian cancers. Radiolabeled with α, Auger, β- or with β+ and gamma/x-rays emitters, they can be used for theranostic purposes.
His radiobiology work is focused on the role of targeted (radiative) and non-targeted (bystander and abscopal) effects of molecular radiotherapy involving intercellular communications and / or the involvement of the immune system. The final aim of his research, led by a multidisciplinary team, is to be transferred to the clinic for optimal cancer diagnosis and treatment.
He has published more than 60 papers and book chapters dealing with radiobiology and radionuclide therapy and several patents. Besides research activity, Dr Pouget is involved in teaching at the University of Montpellier. He is also member of Frontiers in nuclear medicine and Current radiophramaceuticals editorial boards.
Pouget group website